Q-omics provides the consensus-scored MTRF1L profile across patient tissues and cancer cell-line models. MTRF1L expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MTRF1L is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, MTRF1L RNA expression shows 19,529 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and THCA as cancer lineages where MTRF1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTRF1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTRF1L survival associations across molecular data types. MTRF1L RNA expression shows survival associations in the most cancer types (29), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTRF1L RNA expression–survival associations across cancer types. High MTRF1L expression shows unfavorable associations in ACC, LIHC, KIRP, BLCA and MESO, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MTRF1L RNA expression.
This table summarizes MTRF1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MTRF1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTRF1L shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, HNSC, CHOL and STAD. The THCA box plot shows higher MTRF1L RNA expression in normal versus tumor tissue (log2 FC = −0.712, t-test p < 0.001).
This table shows molecular features associated with MTRF1L in patient tissues and cancer cell lines. In patient samples, MTRF1L shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MTRF1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
